RECRUITINGOBSERVATIONAL
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
About This Trial
This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)
Who May Be Eligible (Plain English)
Who May Qualify:
1. diagnosed by tissue sample (biopsy-confirmed) PanNEN.
a. The diagnostic biopsy may have been taken from any site (primary or metastatic).
2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years).
3. Participants willing and able to comply with the study procedures.
Who Should NOT Join This Trial:
1. Inability to provide willing to sign a consent form.
2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:
1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
2. Active hematologic malignancy.
3. History of allogenic bone marrow transplant or stem cell transplant.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Histologically confirmed PanNEN.
a. The diagnostic biopsy may have been taken from any site (primary or metastatic).
2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years).
3. Participants willing and able to comply with the study procedures.
Exclusion Criteria:
1. Inability to provide informed consent.
2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:
1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
2. Active hematologic malignancy.
3. History of allogenic bone marrow transplant or stem cell transplant.
Treatments Being Tested
DIAGNOSTIC_TEST
Hereditary Cancer Panel
UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
Locations (3)
University of California, Los Angeles
Los Angeles, California, United States
Univeristy of California, San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States